Please login to the form below

Not currently logged in

Price tags on drug packs just ‘headline grabbing gimmick’

BMJ journal DTB says it could make cheaper drugs seem less important


Adding the price tags to prescription medicines in England is just a “headline grabbing gimmick,” which could mislead patients into believing cheaper drugs are somehow less important.

This is according to a new editorial in Drug and Therapeutics Bulletin, the drug and medicines journal run by The BMJ publisher.

On 1 July this year, health secretary for England Jeremy Hunt announced plans to print the indicative cost of medicines on all packs of those worth more than £20 alongside the phrase “funded by the UK taxpayer.”

The initiative aims to encourage more people to take personal responsibility for the use of finite public resources, added to which the health secretary claimed that the move would help cut waste and improve patient care as more people would be inclined to take their meds.

But dtb is unconvinced and in its new editorial, the journal says there is no evidence to back the move, nor does such a strategy feature in any national or international guidance on ways of making sure people stick to their prescribed drug regimen.

Sticking to a prescribed course of drugs can be difficult even for those who pay for their prescriptions, it says, adding that the approach could have several unintended consequences.

These include worrying elderly or vulnerable patients, such as the mentally ill, who may see themselves as a burden on society and consequently not take their medication, or leading people to view cheaper drugs as less important, says the editorial.

Last year, the average cost of medicines dispensed in England was £8.32, with drugs costing under £20 comprising a far higher volume than those costing more than £20, it says.

“Although there is no link between the NHS price of a medicine and its clinical efficacy, we believe that there is a risk that the price might be misinterpreted as an indicator of the medicine's value,” says the editorial.

“A patient taking a number of drugs may gain a biased understanding of their treatment, with inexpensive drugs used for heart disease being considered less important than a high cost drug used to treat pain,” it continues.

Furthermore, the price of a drug may not represent the true cost to the NHS, because some cheap drugs are expensive in terms of the monitoring and follow up they require, the editorial points out.

There are practical considerations, as well, says dtb, including who is going to foot the cost of the changes required to the packaging. And many containers are already small, making it hard to include the mandatory dosing information and warnings, let alone anything else, it says.

Further crowding of the container with extra words could make other far more important information less clear, and potentially lead to mistakes being made, it suggests.

Improving a patient's willingness/ability to stay the course of treatment requires some investment, in terms of the time needed to have an informed two way discussion with the patient, and this may ultimately be far more useful than simply including the price tag on the container, says dtb.

“The most expensive drugs are the ones dispensed but never used, and it is not clear that this headline grabbing gimmick will do anything to improve adherence,” it concludes.

Article by
Ben Adams

6th August 2015

From: Healthcare



Featured jobs

Subscribe to our email news alerts


Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....